Overview With the extremely successful launch of Vyndamax for the treatment of patients with transthyretin amyloid cardiomyopathy (ATTR-CM), Pfizer has established Vyndamax as the global leader in the field of amyloidosis. Vyndamax is a US Commercial priority and the anchor brand for the Specialty Care. With two new competitive entrants and an additional potential entrant expected in early 2027, positioning Vyn for continued leadership is critical for Pfizer. As the brand advances through its l…
Completá tu perfil y te avisamos cuando se publiquen concursos y oportunidades laborales en las cuales puedas aplicar o se ajusten a ti.
Para que te mantengamos informado de empleos como este — US Vyndamax Associate
Deja de buscar. Tu próximo trabajo ya está en tu bolsillo. Oportunidades que se adaptan a ti, no al revés.